- Home
- IONS vs TMHC Comparison
IONS vs TMHC Comparison
Compare IONS & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- TMHC
- Stock Information
- Founded
- IONS 1989
- TMHC 1936
- Country
- IONS United States
- TMHC United States
- Employees
- IONS N/A
- TMHC N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- TMHC Homebuilding
- Sector
- IONS Health Care
- TMHC Consumer Discretionary
- Exchange
- IONS Nasdaq
- TMHC Nasdaq
- Market Cap
- IONS 7.0B
- TMHC 6.9B
- IPO Year
- IONS 1991
- TMHC 2013
- Fundamental
- Price
- IONS $46.89
- TMHC $64.14
- Analyst Decision
- IONS Buy
- TMHC Buy
- Analyst Count
- IONS 18
- TMHC 8
- Target Price
- IONS $61.75
- TMHC $70.17
- AVG Volume (30 Days)
- IONS 969.7K
- TMHC 708.8K
- Earning Date
- IONS 10-31-2024
- TMHC 10-23-2024
- Dividend Yield
- IONS N/A
- TMHC N/A
- EPS Growth
- IONS N/A
- TMHC N/A
- EPS
- IONS N/A
- TMHC 6.73
- Revenue
- IONS $813,460,000.00
- TMHC $7,386,215,000.00
- Revenue This Year
- IONS N/A
- TMHC $6.39
- Revenue Next Year
- IONS $18.53
- TMHC $7.07
- P/E Ratio
- IONS N/A
- TMHC $9.53
- Revenue Growth
- IONS 29.00
- TMHC N/A
- 52 Week Low
- IONS $35.95
- TMHC $37.23
- 52 Week High
- IONS $54.44
- TMHC $69.62
- Technical
- Relative Strength Index (RSI)
- IONS 46.07
- TMHC 49.86
- Support Level
- IONS $46.43
- TMHC $63.70
- Resistance Level
- IONS $50.43
- TMHC $67.78
- Average True Range (ATR)
- IONS 1.46
- TMHC 1.68
- MACD
- IONS -0.07
- TMHC -0.25
- Stochastic Oscillator
- IONS 15.91
- TMHC 24.03
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West and Financial Services. The majority of the company's revenue is derived from its East Segment.